### Learner Notification

**MED Learning Group**

**Seeing Eye to Eye: An Ophthalmology-Primary Care Collaboration Emphasizing the Importance of Screening and Early Diagnosis of Retinopathy in Patients with Diabetes**

**Various Dates: February 13 – June 27, 2023  
Online**

**Acknowledgement of Financial Commercial Support**

Regeneron Pharmaceuticals, Inc.

**Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

**Satisfactory Completion**

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

**Joint Accreditation Statement**

A picture containing drawing

Description automatically generatedIn support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Nurses (ANCC) Credit Designation**

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

###### Objectives - After Attending This Program You Should Be Able To

1. Implement evidence-based recommendations for diabetic retinopathy (DR) screening and monitoring.
2. Investigate available technologies that can help increase screening rates and detection of retinopathy.
3. Describe racial, ethnic and sex variations in the prevalence and disease course of DR and other ocular diseases.
4. Identify the role of VEGF in the development of diabetes-related retinopathy.
5. Examine the importance of early identification and timely treatment of DR and/or DME.
6. Cultivate a team-based approach in caring for the DR patient.
7. Discuss treatments and dosing strategies for the individualized treatment of patients with DR and/or DME.
8. Summarize the systemic and ocular treatments that are effective in the treatment of patients with diabetic eye disease.

**Disclosure of Conflict of Interest**

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

|  |  |  |
| --- | --- | --- |
| **First Name** | **Last Name** | **Commercial Interest: Relationship** |
| Douglas | Cox | NA |
| Ana Maria | Albino | NA |
| Daniel | DaSilva | NA |
| Matthew | Frese | NA |
| Christina | Gallo | NA |
| Nicole | Longo | NA |
| Judy E. | Kim | Alimera Sciences, Allergan, Apellis, Astellas, Bausch and Lomb, Clearside Biomedical, DORC, Genentech, Notal Vision, Novartis, Outlook Therapeutics, Regeneron: Consultant |
| Jessica | Feygin | NA |
| Jo | Shultz | NA |
| Charles P. | Vega | Johnson and Johnson, Boehringer Ingelheim: Consultant |
| Lauren | Welch | NA |

Questions? Email [Certificate@AmedcoEmail.com](mailto:Certificate@AmedcoEmail.com)